Accueil>>Signaling Pathways>> Others>>LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

Catalog No.GC34168

Le dichlorhydrate de LCL521 (dichlorhydrate de 1,3DMG-B13) est un inhibiteur de la céramidase acide (ACDase). LCL521 inhibe également la sphingomyélinase acide lysosomale (ASMase).

Products are for research use only. Not for human use. We do not sell to patients.

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride) Chemical Structure

Cas No.: 1226759-47-2

Taille Prix Stock Qté
10mM (in 1mL DMSO)
462,00 $US
En stock
5mg
315,00 $US
En stock
10mg
495,00 $US
En stock
50mg
1 485,00 $US
En stock
100mg
2 385,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride) is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).

LCL521 (1 µM) acts as a potent inhibitor of cellular ACDase activity, whereas 10 µM LCL521 has an additional, decreased affect on the α-form of this enzyme. LCL521 (10µM) causes a time-dependent (1 hours and 5 hours) decrease of the α-ACDase form in MCF7 cells[1].

[1]. Bai A, et al. Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15;22(24):6933-44.

Avis

Review for LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.